169 related articles for article (PubMed ID: 38491354)
1. Association of lymphocyte subsets with the efficacy and prognosis of PD‑1 inhibitor therapy in advanced gastric cancer: results from a monocentric retrospective study.
Wang X; Liu X; Dai H; Jia J
BMC Gastroenterol; 2024 Mar; 24(1):113. PubMed ID: 38491354
[TBL] [Abstract][Full Text] [Related]
2. Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study.
Yan Y; Wang X; Liu C; Jia J
BMC Pulm Med; 2022 Apr; 22(1):166. PubMed ID: 35484541
[TBL] [Abstract][Full Text] [Related]
3. Associations between peripheral blood lymphocyte subsets and clinical outcomes in patients with lung cancer treated with immune checkpoint inhibitor.
Li P; Qin P; Fu X; Zhang G; Yan X; Zhang M; Zhang X; Yang J; Wang H; Ma Z
Ann Palliat Med; 2021 Mar; 10(3):3039-3049. PubMed ID: 33849094
[TBL] [Abstract][Full Text] [Related]
4. Predictive response and outcome of peripheral CD4
Gao D; Liu L; Liu J; Liu J
Int Immunopharmacol; 2024 Mar; 129():111663. PubMed ID: 38364744
[TBL] [Abstract][Full Text] [Related]
5. Circulating memory PD-1
Liu J; Liu D; Hu G; Wang J; Chen D; Song C; Cai Y; Zhai C; Xu W
Cancer Cell Int; 2023 Nov; 23(1):274. PubMed ID: 37974194
[TBL] [Abstract][Full Text] [Related]
6. [Effect of dendritic cells on immune function regulated by programmed cell death-1/programmed cell death-ligand 1 in sepsis].
Wang Z; Xie Z; Zhao Y; Bu T; Yu A; Wang S
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2021 Sep; 33(9):1032-1039. PubMed ID: 34839857
[TBL] [Abstract][Full Text] [Related]
7. Association of the CD4
Xu S; Zhu Q; Wu L; Wang Y; Wang J; Zhu L; Zheng S; Hang J
Int Immunopharmacol; 2023 Oct; 123():110642. PubMed ID: 37499395
[TBL] [Abstract][Full Text] [Related]
8. The Predictive Value of Changes in the Absolute Counts of Peripheral Lymphocyte Subsets for Progression and Prognosis in Breast Cancer Patients.
Liu A; Xia Y; Li W; Zhang G; Liu Y; Ye S; Zhao ZR; Yang Y; Jia Y; Guo Y; Liu X; Chen H; Yu J
Contrast Media Mol Imaging; 2022; 2022():3444360. PubMed ID: 36051923
[TBL] [Abstract][Full Text] [Related]
9. [Effect of Pembrolizumab on T Lymphocyte Subsets in Patients with Advanced
Non-small Cell Lung Cancer and Its Therapeutic Effect].
Wang Y; Wang Y; Jiang M; Zhao Y; Zhang X
Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):182-187. PubMed ID: 33819968
[TBL] [Abstract][Full Text] [Related]
10. Prognostic analysis of related factors of adverse reactions to immunotherapy in advanced gastric cancer and establishment of a nomogram model.
He XX; Du B; Wu T; Shen H
World J Gastrointest Oncol; 2024 Apr; 16(4):1268-1280. PubMed ID: 38660670
[TBL] [Abstract][Full Text] [Related]
11. Effect of pembrolizumab on T lymphocyte subsets in patients with advanced oral cancer and its therapeutic effect.
Feng L; Li TK; Yin K; Zhang SX; Chen Z; Bao Y
Medicine (Baltimore); 2022 Sep; 101(36):e30534. PubMed ID: 36086675
[TBL] [Abstract][Full Text] [Related]
12. Changes in T lymphocyte subsets predict the efficacy of atezolizumab in advanced non-small cell lung cancer: a retrospective study.
Wang Y; Zhu J; Zhou N; Wang Y; Zhang X
J Thorac Dis; 2023 Oct; 15(10):5669-5679. PubMed ID: 37969284
[TBL] [Abstract][Full Text] [Related]
13. The alterations in peripheral lymphocyte subsets predict the efficacy and prognosis of immune checkpoint inhibitors in hepatocellular carcinoma.
Xie Q; Hu C; Luo C
J Cancer; 2023; 14(15):2946-2955. PubMed ID: 37781071
[No Abstract] [Full Text] [Related]
14. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
[No Abstract] [Full Text] [Related]
15. Peripheral blood lymphocyte subsets predict the efficacy of TACE with or without PD-1 inhibitors in patients with hepatocellular carcinoma: a prospective clinical study.
Wang H; Huang H; Liu T; Chen Y; Li J; He M; Peng J; Liang E; Li J; Liu W
Front Immunol; 2024; 15():1325330. PubMed ID: 38404585
[TBL] [Abstract][Full Text] [Related]
16. A nomogram model based on peripheral blood lymphocyte subsets to assess the prognosis of non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Xu X; Wang D; Chen W; Li N; Suwinski R; Rossi A; Rosell R; Zhong J; Fan Y
Transl Lung Cancer Res; 2021 Dec; 10(12):4511-4525. PubMed ID: 35070757
[TBL] [Abstract][Full Text] [Related]
17. Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme.
Jan CI; Tsai WC; Harn HJ; Shyu WC; Liu MC; Lu HM; Chiu SC; Cho DY
Front Immunol; 2018; 9():727. PubMed ID: 29910795
[TBL] [Abstract][Full Text] [Related]
18. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
19. Peripheral blood nutrient indices as biomarkers for anti‑PD‑1 therapy efficacy and prognosis in patients with advanced gastric cancer.
Wang X; Liu X; Dai H; Jia J
Oncol Lett; 2023 Sep; 26(3):397. PubMed ID: 37600335
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of NLR, TILs (CD4+/CD8+) and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer.
Zurlo IV; Schino M; Strippoli A; Calegari MA; Cocomazzi A; Cassano A; Pozzo C; Di Salvatore M; Ricci R; Barone C; Bria E; Tortora G; Larocca LM; Basso M; Martini M
Cancer Immunol Immunother; 2022 Jan; 71(1):45-55. PubMed ID: 34009410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]